Description
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry’s greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment.
The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe’s next generation of targeted radiopharmaceuticals. Join your peers to:
Advance Next-Generation Radiopharmaceutical Innovation
Discover the latest breakthroughs across novel targets, alpha emitters, Auger therapies and next-generation radiopharmaceutical platforms to strengthen your discovery and preclinical strategy.
Accelerate Clinical Translation
Learn how leading developers are optimising trial design, dosimetry, combination strategies and earlier-line treatment approaches to generate stronger clinical evidence and maximise patient impact.
Build Resilient Manufacturing and Supply Strategies
Overcome isotope availability, GMP manufacturing, automation, logistics and supply chain bottlenecks to support scalable clinical development and future commercial success.
Navigate Europe’s Evolving Regulatory Landscape
Hear directly from MHRA, Swissmedic, the IAEA and the Office for Nuclear Regulation to understand the latest regulatory expectations and accelerate European clinical and commercial development.
This is your opportunity to join Europe’s most comprehensive, end-to-end forum dedicated to targeted radiopharmaceutical development, where discovery, clinical translation, manufacturing, regulation and commercial strategy come together to accelerate the next generation of radioligand therapies from discovery to patients.
URLs:
Tickets: https://go.evvnt.com/3781817-0?pid=10007
Brochure: https://go.evvnt.com/3781817-2?pid=10007
Website: https://go.evvnt.com/3781817-3?pid=10007
Date and Time: On Tuesday December 01, 2026 at 8:00 am to Thursday December 03, 2026 at 5:00 pm
Venue details: InterContinental London – the O2 by IHG, 1 Waterview Drive, London, England, SE10 0TW, United Kingdom
Category: Conferences
Prices:
Drug Developer Pricing – Full Package: Conference + Workshop Day: GBP 3797.00,
Drug Developer Pricing – Full Package: Conference Only: GBP 2699.00,
Academic Pricing – Full Package: Conference + Workshop Day: GBP 3197.00,
Academic Pricing – Full Package: Conference Only: GBP 2299.00,
Service Provider Pricing – Full Package: Conference + Workshop Day: GBP 4497.00,
Service Provider Pricing – Full Package: Conference Only: GBP 3199.00
Speakers: Guido Würth, Head of Corporate Development and Radiopharma Medical and Health; Sales; Operations, Affibody AB, Fredrik Frejd, Chief Scientific Officer, Affibody AB, Fredrik Frejd, Chief Scientific Officer, Affibody AB, Mark Dornan, Chief Executive Officer, Alpha-9 Oncology, Tanja Aarvak, Director, Program Management, Alpha Radioligand Therapy, ARTBIO, Mark Fielding, Director – Chemistry, Manufacturing, Controls, Regulatory Affairs and Radiopharmaceuticals, AstraZeneca, Sandra Hennig, Vice-President, Head of Regulatory Affairs, Bayer, Zahra Trippe, Patient Engagement Lead Oncology, Bayer, Ming Xu, Vice President, Product Team Lead, Oncology, Bayer, Kevin Tabury, Program Pipeline Manager – Head of Innovation and Translational Development Unit, Belgian Nuclear Research, Graeme McRobbie, Associate Director Formulation Science Radiopharmaceuticals, Bicycle Therapeutics plc, Michael Method, Chief Medical Officer, Bicycle Therapeutics plc, David Gauden, Chief Executive Officer, Blue Earth Therapeutics Ltd., Kemp Dolliver, Director of Research, Brookline Capital Markets, Mohamad Haqiqian, PET Radiopharmacy Production and QC Analyst, Radiation Safety Supervisor, Curium Pharma, Christopher Jones, UK Representative to IAEA Transport Safety Standards Committee/Principal Inspector, IAEA/Office for Nuclear Regulations, Kristoffer Danielsson, CEO, Jarlen Capital, Kurt Pike, Senior Director – External Innovation, Johnson and Johnson, Cara Ferreira, Chief Executive Officer, Lumina Pharmaceuticals, Judson Kimmel, Patient Advocate, Man Up To Cancer, Gary Inwards, Sr Pharmaceutical Assessor, MHRA, Martin Steegmaier, Chief Scientific Officer, Molecular Partners, Chris Pak, President and Chief Executive Officer, Molecular Targeting Technologies, Waisi Eng, Chief Technology Officer, Norroy Bioscience CO., LTD, Ilya Folitar, Job title not listed, Company not listed, Chaitanya Divgi, Sr Strategic Expert, Novartis, Ana Filipa Fonseca, Director – Global Radioligand Therapy, Strategy and Early Portfolio, Novartis AG, Shefali Kakar, Vice President, Global Head PK Sciences – Oncology, Novartis AG, Muhammet Tanc, CEO, Nuclide Therapeutics, Rich Edwards, Chief Technology Officer, Nuclide Therapeutics, Oystein Soug, Chief Executive Officer, Oncoinvent AS, Friedmund Bachmann, Vice President – Chemistry, Manufacturing and Control, OncoOne, Frederic Desdouits, Chief Executive Officer, OranoMed, Dirk Pleimes, Group Chief Executive Officer and Chief Marketing Officer, PentixaPharm GmbH, Josie Gayton, Chief Operating Officer, Precirix, Guangzhou Han, Chief Scientific Officer, RadAlliance Therapeutics Inc, John Babich, President and Chief Scientific Officer, Ratio Therapeutics, Inc., Dangshe Ma, Senior Director, Regeneron Pharmaceuticals, Julie Martin, President and Chief Executive Officer, Scimega Research, Richard Pearson, CEO, StandardX, Andreas Furer, Senior Regulatory Manager, Swiss Medic, Marc Robillard, Chief Scientific Officer and Founder, Tagworks Pharmaceuticals BV, Anil Lalwani, Director – Regulatory Chemistry Manufacturing and Controls and MedTech, Telix Pharmaceuticals, Ajaaz Hussain, Radiopharmaceutical Scientist (Clinical Trials), The Royal Marsden NHS, Tinashe Chandauka, Co-Founder and Chief Executive Officer, TMab Therapeutics, Luke Brzozowski, Executive Director – Translational Research and Core Facilities, Program Sponsor, Theranostics, UHN, Julia Publicover, Director, Translational Research and Innovation, University Health Network, Luigi Aloj, Professor of Nuclear Medicine, University of Cambridge, Haihong Jin, Chief Scientific Officer, Vitsgen Therapeutics, Inc.